FBIO - Fortress Biotech Inc. Pre-PDUFA Catalyst PlayFortress Biotech, Inc.NASDAQ:FBIOmeitshels_smell_tradesFortress Biotech, Inc. (FBIO) - Company Overview Fortress Biotech, Inc. is a biopharmaceutical company dedicated to advancing and commercializing innovative therapies. It focuses on the development of treatments for oncology, dermatology, and other therapeutic areas. Fortress Biotech operates a robust pipeline, including both preclinical and clinical-stage assets. The company's goal is to drive value through strategic acquisitions, product approvals, and partnerships to bring novel therapies to market. Fortress Biotech, Inc. (FBIO) - Pre-PDUFA Catalyst Play with Latest News Entry Zone: Current Price: ~$2.58 Ideal Entry: Enter at or near the $2.58 price point for the best setup ahead of the PDUFA catalyst on 30/09/2025. Resistance Levels: First Resistance: $3.00 A breakout above $3.00 could signal the next leg up. Take Profit Zones: TP 1: $4.40 Target for short-term profits, likely as the stock runs into resistance zones. TP 2: $7.50 This level represents a longer-term potential if momentum persists and the stock continues upward. Stop Loss (SL): Stop Loss Level: $1.90 A drop below $1.90 would invalidate the pre-run-up setup and suggest further downside risk. Trade Strategy: Pre-Run-Up Play: Focus on capitalizing on potential gains before the PDUFA catalyst announcement. Sell Before the News: It's important to exit before the PDUFA announcement on 30/09/2025 to avoid post-catalyst volatility. Recent News Impacting FBIO: Friday, August 22, 2025 "Fortress Biotech's Strong Financial Prospects Bolstered by Strategic Acquisitions and Product Approvals" Positive news reflecting the company’s growing potential through acquisitions and new product approvals. Thursday, August 21, 2025 "HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17" Friday, August 15, 2025 "Fortress Biotech shares are trading higher after the company reported better-than-expected Q2 sales results." Strong Q2 performance has boosted investor sentiment. Friday, August 15, 2025 "Journey Medical's Q2 2025: Emrosi Gains Traction" This is an earnings release that ties into the broader narrative of growth and progress for related companies in the sector. Conclusion: FBIO is positioning itself for a pre-run-up play ahead of its PDUFA catalyst on 30/09/2025. With the entry point at $2.58, first resistance at $3.00, and take-profit zones at $4.40 and $7.50, there’s solid potential for short-term gains. Keep a stop-loss at $1.90 for risk management. Sell before the catalyst news to avoid post-announcement volatility. Recent news has provided a mixture of positive and neutral sentiment. Positive developments like better-than-expected Q2 results and strategic acquisitions should help support upward momentum. However, the lowered price target from Roth Capital could limit upside potential in the short term. Make sure to watch market reactions closely as the PDUFA date approach. Disclaimer: This content is for informational purposes only and should not be considered as financial or investment advice. The analysis provided is based on publicly available information and the user’s personal research. Investing in stocks carries inherent risks, and it is important to conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions. The user assumes all responsibility for their own investment actions.